E Merck's float raises $1.4 billion:
This article was originally published in Clinica
Executive Summary
E Merck, the German pharmaceutical and laboratory supplies company, has raised DM 2,100 million ($1,400 million) from the largest ever public share offering in Germany. In the five-times subscribed offer, E Merck sold 40 million shares, 25% of its enlarged capital, at a price of DM 54 each. This was close to the top of the range of DM 46-56 indicated for the book building process which preceded the float. The shares started trading on the Frankfurt and Zurich stock exchanges on October 20th.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.